Show simple item record

dc.contributor.authorAngeletti, Carlo
dc.contributor.authorAmici, Adolfo
dc.contributor.authorGilley, Jonathan
dc.contributor.authorLoreto, Andrea
dc.contributor.authorTrapanotto, Antonio G
dc.contributor.authorAntoniou, Christina
dc.contributor.authorMerlini, Elisa
dc.contributor.authorColeman, Michael
dc.contributor.authorOrsomando, Giuseppe
dc.date.accessioned2022-03-08T00:30:19Z
dc.date.available2022-03-08T00:30:19Z
dc.date.issued2022-02-18
dc.identifier.issn2589-0042
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334739
dc.description.abstractSARM1 is an NAD(P) glycohydrolase and TLR adapter with an essential, prodegenerative role in programmed axon death (Wallerian degeneration). Like other NAD(P)ases, it catalyzes multiple reactions that need to be fully investigated. Here, we compare these multiple activities for recombinant human SARM1, human CD38, and Aplysia californica ADP ribosyl cyclase. SARM1 has the highest transglycosidation (base exchange) activity at neutral pH and with some bases this dominates NAD(P) hydrolysis and cyclization. All SARM1 activities, including base exchange at neutral pH, are activated by an increased NMN:NAD ratio, at physiological levels of both metabolites. SARM1 base exchange occurs also in DRG neurons and is thus a very likely physiological source of calcium-mobilizing agent NaADP. Finally, we identify regulation by free pyridines, NADP, and nicotinic acid riboside (NaR) on SARM1, all of therapeutic interest. Understanding which specific SARM1 function(s) is responsible for axon degeneration is essential for its targeting in disease.
dc.format.mediumElectronic-eCollection
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBiological sciences
dc.subjectMolecular physiology
dc.subjectNeuroscience
dc.titleSARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated bymultiple physiologically relevant NAD metabolites.
dc.typeArticle
dc.publisher.departmentJohn Van Geest Centre For Brain Repair
dc.publisher.departmentDepartment of Clinical Neurosciences
dc.date.updated2022-03-04T17:10:46Z
prism.issueIdentifier2
prism.number103812
prism.publicationDate2022
prism.publicationNameiScience
prism.startingPage103812
prism.volume25
dc.identifier.doi10.17863/CAM.82169
dcterms.dateAccepted2022-01-20
rioxxterms.versionofrecord10.1016/j.isci.2022.103812
rioxxterms.versionVoR
dc.contributor.orcidLoreto, Andrea [0000-0001-6535-6436]
dc.contributor.orcidColeman, Michael [0000-0002-9354-532X]
dc.identifier.eissn2589-0042
rioxxterms.typeJournal Article/Review
pubs.funder-project-idBiotechnology and Biological Sciences Research Council (BB/S009582/1)
pubs.funder-project-idWellcome Trust (210904/Z/18/Z)
cam.issuedOnline2022-02-18
cam.depositDate2022-03-04
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International